Alzheimer’s Tied to Military Service; Long COVID Sleepiness; NurOwn Tries Again

Derick Alison
Derick Alison
2 Min Read

Military service was linked with Alzheimer’s disease neuropathology at autopsy. (Alzheimer’s and Dementia)

Ten hours of acoustic stimulation while resting in a zero-gravity chair improved post-concussive symptoms. (Annals of Clinical and Translational Neurology)

Long-term effects of amyloid-related imaging abnormalities (ARIA) — a side effect of Alzheimer’s drugs like lecanemab (Leqembi) — need to be reported, an NIH researcher advocated. (STAT)

Neuropsychiatric symptoms like irritability were linked with microglial activation in Alzheimer’s disease. (JAMA Network Open)

Undiagnosed obstructive sleep apnea syndrome emerged as a treatable cause of new-onset sleepiness in some long COVID patients. (European Journal of Neurology)

Small sounds generated in the ear by the brain contained accurate information about contemporaneous eye movements. (PNAS)

Alzheimer’s disease was positively correlated with inflammatory biomarkers in plasma. (Alzheimer’s and Dementia)

Biological sex may influence the role of amyloid-beta on tau phosphorylation and underlie faster tangle accumulation in women with Alzheimer’s. (Brain)

BrainStorm Cell Therapeutics said the FDA agreed to discuss the protocol design for a phase III trial of its mesenchymal stromal cells secreting neurotrophic factors therapy (NurOwn) in ALS. In September, an FDA panel overwhelmingly rejected the investigational cell therapy.

Shoulder-fired rockets expose U.S. troops to shock waves above safety limits, but they remain in wide use despite known brain risks. (New York Times)

Large language models used routine clinical notes to predict seizure recurrence. (Lancet Digital Health)

Scott Ramsay, PhD, a former Western Hockey League player who is now a concussion researcher, called for better follow-up care for kids with head injuries. (CTV News Vancouver)

Asklepios BioPharmaceutical said the first patient was randomized in its phase I trial of AB-1005 gene therapy for multiple system atrophy-parkinsonian type.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Source link

Share this Article
Leave a comment